European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 242-252 , May 2009

Genetic susceptibility to systemic sclerosis: From clinical aspect to genetic factor analyses

  • Brigitte Granel

      Affiliations

    • INSERM, U906, Marseille, F-13385, France
    • Service de Médecine Interne, Hôpital Nord, Assistance Publique Hôpitaux de Marseille (AP-HM), chemin des Bourrely, 13915 Marseille Cedex 20, France
    • Corresponding Author InformationCorresponding author. INSERM, U906 et Laboratoire de Parasitologie et de Mycologie, Marseille, F-13385, France. Tel.: +33 4 91 32 45 23; fax: +33 4 91 79 60 63.
    • ,
  • Fanny Bernard

      Affiliations

    • INSERM, U906, Marseille, F-13385, France
    • ,
  • Christophe Chevillard

      Affiliations

    • INSERM, U906, Marseille, F-13385, France
    • Laboratoire de Parasitologie et de Mycologie, Faculté de Médecine, Université de la Méditerranée, Marseille, F-13385, France

Received 25 March 2008 ,Revised 18 June 2008 ,Accepted 7 July 2008.

References 

  1. Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum. 2007;56(8):2740–2746
  2. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998;17(1):48–54
  3. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum. 2007;56(7):2422–2431
  4. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev. 2007;6(8):520–523
  5. Cutolo M, Pizzorni C, Tuccio M, Burroni A, Craviotto C, Basso M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford). 2004;43(6):719–726
  6. Allanore Y, Seror R, Chevrot A, Kahan A, Drape JL. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum. 2007;56(8):2747–2754
  7. Marie I. Gastrointestinal involvement in systemic sclerosis. Presse Med. 2006;35(12 Pt 2):1952–1965
  8. Highland KB, Garin MC, Brown KK. The spectrum of scleroderma lung disease. Semin Respir Crit Care Med. 2007;28(4):418–429
  9. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol. 2007;34(5):1005–1011
  10. Launay D, Humbert M, Hachulla E. Pulmonary arterial hypertension and systemic sclerosis. Presse Med. 2006;35(12 Pt 2):1929–1937
  11. van Laar JM, Stolk J, Tyndall A. Scleroderma lung: pathogenesis, evaluation and current therapy. Drugs. 2007;67(7):985–996
  12. Allanore Y, Kahan A. Heart involvement in systemic sclerosis. Presse Med. 2006;35(12 Pt 2):1938–1942
  13. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29(2):315–333
  14. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. Qjm. 2007;100(8):485–494
  15. Teixeira L, Mouthon L, Mahr A, Berezné A, Agard C, Mehrenberger M, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis. 2008;67(1):110–116
  16. Preliminary criteria for the classification of systemic sclerosis (scleroderma) . Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581–590
  17. Johnson SR, Laxer RM. Classification in systemic sclerosis. J Rheumatol. 2006;33(5):840–841
  18. Nadashkevich O, Davis P, Fritzler MJ. Revising the classification criteria for systemic sclerosis. Arthritis Rheum. 2006;55(6):992–993
  19. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202–205
  20. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81(2):154–167
  21. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford). 2005;44(10):1212–1216
  22. Granel B, Chevillard C, Dessein A. [Genetic factors predisposing to fibrosis in systemic sclerosis]. Rev Med Interne. 2005;26(4):294–303
  23. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep. 2002;4(2):99–107
  24. Artlett CM. Immunology of systemic sclerosis. Front Biosci. 2005;10:1707–1719
  25. Whiteside TL, Medsger TA, Rodnan GP. HLA-DR antigens in progressive systemic sclerosis (scleroderma). J Rheumatol. 1983;10(1):128–131
  26. Steen VD, Ziegler GL, Rodnan GP, Medsger TA. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984;27(2):125–131
  27. Reveille JD, Durban E, MacLeod-St Clair MJ, Goldstein R, Moreda R, Altman RD, et al. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest. 1992;90(3):973–980
  28. Feghali-Bostwick C, Medsger TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48(7):1956–1963
  29. Zhou X, Tan FK, Xiong M, Arnett FC, Feghali-Bostwick CA. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum. 2005;52(10):3305–3314
  30. Pablos JL, Everett ET, Norris JS. The tight skin mouse: an animal model of systemic sclerosis. Clin Exp Rheumatol. 2004;22(3 Suppl 33):S81–85
  31. Jimenez SA, Christner PJ. Murine animal models of systemic sclerosis. Curr Opin Rheumatol. 2002;14(6):671–680
  32. Zhang Y, Gilliam AC. Animal models for scleroderma: an update. Curr Rheumatol Rep. 2002;4(2):150–162
  33. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med. 2004;140(1):37–50
  34. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26(11):587–595
  35. Assassi S, Tan FK. Genetics of scleroderma: update on single nucleotide polymorphism analysis and microarrays. Curr Opin Rheumatol. 2005;17(6):761–767
  36. Allanore Y, Wipff J, Kahan A, Boileau C. Genetic basis for systemic sclerosis. Joint Bone Spine. 2007;74(6):577–583
  37. Kawaguchi Y, McCarthy SA, Watkins SC, Wright TM. Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol. 2004;31(10):1946–1954
  38. Kawaguchi Y, Hara M, Kamatani N, Wright TM. Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis. Arthritis Rheum. 2003;48(1):193–202
  39. Mattuzzi S, Barbi S, Carletto A, Ravagnani V, Moore PS, Bambara LM, et al. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol. 2007;34(5):997–1004
  40. Hutyrova B, Lukac J, Bosak V, Buc M, du Bois R, Petrek M. Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis. J Rheumatol. 2004;31(1):81–84
  41. Beretta L, Cappiello F, Moore JH, Scorza R. Interleukin-1 gene complex single nucleotide polymorphisms in systemic sclerosis: a further step ahead. Hum Immunol. 2008;69(3):187–192
  42. Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest. 1994;94(6):2489–2492
  43. Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun. 2001;281(1):200–205
  44. Hudson LL, Rocca KM, Kuwana M, Pandey JP. Interleukin-10 genotypes are associated with systemic sclerosis and influence disease-associated autoimmune responses. Genes Immun. 2005;6(3):274–278
  45. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of the 5¢ flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology (Oxford). 2003;42(11):1295–1298
  46. Granel B, Chevillard C, Dessein A. Interleukin 13 and interleukin 13 receptor involvement in systemic sclerosis. Rev Med Interne. 2007;28(9):613–622
  47. Granel B, Chevillard C, Allanore Y, Arnaud V, Cabantous S, Marquet S, et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics. 2006;58(8):693–699
  48. Granel B, Allanore Y, Chevillard C, Arnaud V, Marquet S, Weiller PJ, et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol. 2006;33(10):2015–2019
  49. Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol. 2003;171(7):3855–3862
  50. Sato H, Lagan AL, Alexopoulou C, Vassilakis DA, Ahmad T, Pantelidis P, et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum. 2004;50(2):558–564
  51. Tolusso B, Fabris M, Caporali R, Cuomo G, Isola M, Soldano F, et al. −238 and + 489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunol Lett. 2005;96(1):103–108
  52. Takeuchi F, Nabeta H, Fussel M, Conrad K, Frank KH. Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis. 2000;59(4):293–296
  53. Pandey JP, Takeuchi F. TNF-alpha and TNF-beta gene polymorphisms in systemic sclerosis. Hum Immunol. 1999;60(11):1128–1130
  54. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. Faseb J. 2004;18(7):816–827
  55. Querfeld C, Eckes B, Huerkamp C, Krieg T, Sollberg S. Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci. 1999;21(1):13–22
  56. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis. 2002;61(8):678–681
  57. Sugiura Y, Banno S, Matsumoto Y, Niimi T, Yoshinouchi T, Hayami Y, et al. Transforming growth factor beta1 gene polymorphism in patients with systemic sclerosis. J Rheumatol. 2003;30(7):1520–1523
  58. Zhou X, Tan FK, Stivers DN, Arnett FC. Microsatellites and intragenic polymorphisms of transforming growth factor beta and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (scleroderma): a preliminary analysis showing no genetic association. Arthritis Rheum. 2000;43(5):1068–1073
  59. Pandey JP, LeRoy EC. A profibrotic polymorphism (of TGFbeta1) in systemic sclerosis. Ann Rheum Dis. 2002;61(8):671–672
  60. Susol E, Rands AL, Herrick A, McHugh N, Barrett JH, Ollier WE, et al. Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. Rheumatology (Oxford). 2000;39(12):1332–1336
  61. Leask A. Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J Med. 2004;53(2):74–77
  62. Takehara K. Hypothesis: pathogenesis of systemic sclerosis. J Rheumatol. 2003;30(4):755–759
  63. Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med. 2007;357(12):1210–1220
  64. Gourh P, Mayes MD, Arnett FC. CTGF polymorphism associated with systemic sclerosis. N Engl J Med. 2008;358(3):308–309author reply 9
  65. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996;271(30):17779–17784
  66. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol. 2003;15(6):772–777
  67. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001;44(11):2665–2678
  68. Karrer S, Bosserhoff AK, Weiderer P, Distler O, Landthaler M, Szeimies RM, et al. The −2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis. J Invest Dermatol. 2005;124(1):92–98
  69. Renzoni E, Lympany P, Sestini P, Pantelidis P, Wells A, Black C, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 2000;43(7):1633–1640
  70. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Lack of association of eNOS (G894T) and p22phox NADPH oxidase subunit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients. Clin Chim Acta. 2004;350(1–2):51–55
  71. Allanore Y, Borderie D, Airo P, Guiducci S, Czirják L, Nasonov EL, et al. Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis. 2007;66(2):257–259
  72. Pushpakom SP, Herrick AL, Kumar S, Worthington J. Polymorphisms in COL15 gene are not associated with systemic sclerosis. J Rheumatol. 2008;35(2):251–253
  73. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol. 2002;29(11):2379–2381
  74. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet. 2002;3(5):391–397
  75. Fonseca C, Denton CP. Genetic association studies in systemic sclerosis: more evidence of a complex disease. J Rheumatol. 2007;34(5):903–905
  76. Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, Reveille JD, et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum. 2003;48(9):2585–2592
  77. Zhou X, Tan FK, Reveille JD, Wallis D, Milewicz DM, Ahn C, et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum. 2002;46(11):2990–2999
  78. Lagan AL, Pantelidis P, Renzoni EA, Fonseca C, Beirne P, Taegtmeyer AB, et al. Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology (Oxford). 2005;44(2):197–201
  79. Hata R, Akai J, Kimura A, Ishikawa O, Kuwana M, Shinkai H. Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Commun. 2000;272(1):36–40
  80. Tan FK, Stivers DN, Foster MW, Chakraborty R, Howard RF, Milewicz DM, et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum. 1998;41(10):1729–1737
  81. Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DM, et al. Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum. 2001;44(4):893–901
  82. Wipff J, Giraud M, Sibilia J, Mouthon L, Meyer O, Tiev K, et al. Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol. 2008;35(4):643–649(Apr)
  83. Avila JJ, Lympany PA, Pantelidis P, Welsh KI, Black CM, du Bois RM. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol. 1999;20(1):106–112
  84. Fonseca C, Renzoni E, Sestini P, Pantelidis P, Lagan A, Bunn C, et al. Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 2006;54(9):3034–3042
  85. Wipff J, Kahan A, Hachulla E, Sibilia J, Cabane J, Meyer O, et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford). 2007;46(4):622–625
  86. Fatini C, Gensini F, Sticchi E, Battaglini B, Angotti C, Conforti ML, et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med. 2002;112(7):540–544
  87. Assassi S, Mayes MD, McNearney T, Fischbach M, Reveille JD, Arnett FC, et al. Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. Am J Med. 2005;118(8):907–911
  88. Hudson LL, Silver RM, Pandey JP. Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J Rheumatol. 2004;31(1):85–87
  89. Almasi S, Erfani N, Mojtahedi Z, Rajaee A, Ghaderi A. Association of CTLA-4 gene promoter polymorphisms with systemic sclerosis in Iranian population. Genes Immun. 2006;7(5):401–406
  90. Takeuchi F, Kawasugi K, Nabeta H, Mori M, Tanimoto K. Association of CTLA-4 with systemic sclerosis in Japanese patients. Clin Exp Rheumatol. 2002;20(6):823–828
  91. Takeuchi F, Nakaue N, Kawasugi K, Mori M, Kuwata S, Tanimoto K. The CTLA-4 −1661A/G and −1772T/C dimorphisms in Japanese patients with systemic sclerosis. Rheumatol Int. 2007;27(8):785–787
  92. Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K, et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum. 2004;50(12):4002–4007
  93. Gourh P, Tan FK, Assassi S, Ahn CW, McNearney TA, Fischbach M, et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum. 2006;54(12):3945–3953
  94. Wipff J, Allanore Y, Kahan A, Meyer O, Mouthon L, Guillevin L, et al. Lack of association between the protein tyrosine phosphatase non-receptor 22 (PTPN22)⁎620W allele and systemic sclerosis in the French Caucasian population. Ann Rheum Dis. 2006;65(9):1230–1232

☆ Please see related article in this issue: localized scleroderma: A series of 52 patients, Toledano C. et al.

PII: S0953-6205(08)00212-4

doi: 10.1016/j.ejim.2008.07.012

European Journal of Internal Medicine
Volume 20, Issue 3 , Pages 242-252 , May 2009

Article Tools